FDA decides on gedatolisib July 17, 2026, for HR+/HER2-/PIK3CA wild-type advanced breast cancer. A Phase 3 trial showed 76% risk reduction in progression. 37,000 patients per year.
A Breast Cancer Drug Decision Due July 17 Could Open a New Treatment Path for 37,000 Women a Year Who Have No Good Options Now
by | Jul 13, 2026 | Uncategorized | 0 comments
Recent Comments